Methotrexate cerebrospinal fluid pharmacokinetics in a patient with lymphoma treated with methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone.

[1]  M. Oken,et al.  CENTRAL NERVOUS SYSTEM RELAPSE IN UNFAVOURABLE-HISTOLOGY NON-HODGKIN'S LYMPHOMA: IS PROPHYLAXIS INDICATED? , 1984, The Lancet.

[2]  G. Curt,et al.  The pharmacology and clinical use of methotrexate. , 1983, The New England journal of medicine.

[3]  G. Pinkus,et al.  Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Jones,et al.  Involvement of the central nervous system by non‐Hodgkin's lymphoma. The southwest oncology group experience , 1979, Cancer.

[5]  A. Freeman,et al.  High-dose methotrexate in acute lymphocytic leukemia. , 1977, Cancer treatment reports.

[6]  W. Shapiro,et al.  Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. , 1975, The New England journal of medicine.

[7]  B. Chabner,et al.  Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. , 1973, The Journal of clinical investigation.

[8]  J. Bertino,et al.  Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. , 1969, The Journal of clinical investigation.

[9]  A. Bleyer,et al.  Altered central nervous system pharmacology of methotrexate in childhood leukemia: another sign of meningeal relapse. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  W. Shapiro,et al.  Serum and cerebrospinal fluid distribution of 5-methyltetrahydrofolate after intravenous calcium leucovorin and intra-Ommaya methotrexate administration in patients with meningeal carcinomatosis. , 1983, Cancer research.